Triveni Bio's Dual-Action Drug Aims to Break Eczema Treatment Ceiling

WATERTOWN, Mass. – May 18, 2026 – Triveni Bio, a clinical-stage biotechnology company, has initiated a Phase 1 clinical trial for a next-generation therapy that could represent a paradigm shift in the treatment of atopic dermatitis (AD), a chronic and debilitating form of eczema. The company announced it has dosed the first healthy volunteers with TRIV-573, a novel bispecific antibody designed to simultaneously repair the skin's protective barrier and quell the underlying inflammation that drives the disease.

This move propels a first-in-class therapeutic into human trials, offering a new front in the battle against a condition that affects millions worldwide. By uniquely combining two distinct mechanisms of action into a single molecule, Triveni Bio aims to overcome the limitations of current treatments and address the significant unmet needs of patients with moderate-to-severe atopic dermatitis.

A New Strategy for a Complex Disease

The market for atopic dermatitis treatments is a multi-billion dollar arena, projected to surge past $22 billion by 2034. It is currently dominated by highly successful biologics like Dupixent (dupilumab), which blocks the inflammatory pathways of Interleukin-4 (IL-4) and Interleukin-13 (IL-13), and a growing class of oral JAK inhibitors such as Rinvoq (upadacitinib) and Cibinqo (abrocitinib). While these drugs have transformed patient care, providing significant skin clearance and itch relief for many, a notable portion of patients still experience persistent symptoms.

This phenomenon has led researchers to posit the existence of a "Th2 efficacy ceiling," suggesting that targeting the Type 2 inflammatory pathway alone—the primary mechanism of most modern biologics—may not be sufficient to achieve complete or lasting disease control for everyone. A key reason is that atopic dermatitis is a two-pronged problem: it involves both immune system dysregulation and a fundamental defect in the skin barrier.

TRIV-573 is engineered to tackle both problems head-on. It combines the established anti-inflammatory power of an IL-13 blockade with a novel mechanism designed to restore the skin's structural integrity by inhibiting the enzymes kallikrein 5 and 7 (KLK5/7).

The Science of Dual Inhibition: KLK5/7 and IL-13

At the heart of Triveni Bio's strategy is a deep understanding of AD's complex pathology. IL-13 is a well-known cytokine central to the Type 2 inflammation that causes the intense itch and rash characteristic of eczema. By blocking IL-13, TRIV-573 employs a validated anti-inflammatory approach similar to that of successful drugs like Adbry (tralokinumab) and Ebglyss (lebrikizumab).

However, the drug's innovation lies in its second target. In healthy skin, the enzymes KLK5 and KLK7 help regulate the normal shedding of skin cells. In patients with atopic dermatitis, these proteases are overactive, leading to the excessive breakdown of proteins that hold the outer layer of the skin—the stratum corneum—together. This enzymatic degradation contributes directly to a leaky, compromised skin barrier, allowing allergens and irritants to penetrate, which in turn triggers more inflammation in a vicious cycle.

By inhibiting KLK5 and KLK7, TRIV-573 aims to stop this destructive process, allowing the skin barrier to repair itself. This orthogonal approach of simultaneously building up the barrier while shutting down inflammation is what sets the therapy apart.

"TRIV-573 builds on compelling preclinical evidence that KLK5/7 inhibition addresses all three pillars of AD pathology: barrier, inflammation, and itch," said Bhaskar Srivastava, M.D., Ph.D., Chief Medical Officer of Triveni Bio, in the company's press release. "We have demonstrated preclinical additivity when combining the KLK5/7 mechanism with Th2 targeting, positioning TRIV-573 as a novel combination approach for moderate-to-severe AD with a single therapeutic designed for infrequent, patient-friendly dosing."

Triveni's Expanding Pipeline and Market Position

The initiation of the TRIV-573 trial marks a period of rapid execution for Triveni Bio, which emerged from stealth in January 2024 with a substantial $82 million Series A financing. The funding round, co-led by prominent investors Orbimed and Atlas Venture and including pharmaceutical giant Bristol Myers Squibb, provides a strong financial runway to advance its ambitious pipeline.

The company is pursuing a dual-pronged strategy in atopic dermatitis. Its lead program, TRIV-509, is a monoclonal antibody that targets only KLK5/7 and is currently in a Phase 2 proof-of-concept trial. TRIV-573 represents a second-generation approach, building on the KLK5/7 mechanism by adding the anti-IL-13 component to create a more powerful, bispecific therapy.

"Advancing TRIV-573 into the clinic less than one year after TRIV-509 is a testament to our team's execution," stated Vishal Patel, Ph.D., Chief Executive Officer. "We are thrilled to progress this unique therapy as we work to break the existing efficacy ceiling for patients with AD and other I&I disorders."

This strategic advancement of two distinct but related assets showcases the company's genetics-informed approach, which seeks to leverage deep biological insights to create precision treatments for complex immunological diseases.

What's Next for TRIV-573 and Patients

With the Phase 1 study in healthy volunteers now underway to assess safety and pharmacokinetics, Triveni Bio is already looking ahead. The company plans to initiate a Phase 2 proof-of-concept study in patients with moderate-to-severe atopic dermatitis in the second half of 2026. This trial will provide the first crucial data on whether the dual-inhibition hypothesis translates into superior clinical outcomes for patients.

If successful, TRIV-573 could offer a significant advantage: a single, infrequently dosed injection that provides more comprehensive disease control than existing options. For patients who have not found adequate relief with current therapies, or who struggle with the burden of persistent symptoms despite treatment, this dual-action approach offers a new wave of hope.

The path through clinical development is long and fraught with challenges, but the scientific rationale behind TRIV-573 is compelling. As the trial progresses, the dermatology and investment communities will be watching closely to see if this innovative bispecific antibody can indeed repair the barrier, silence the inflammation, and ultimately raise the bar for treating atopic dermatitis.